HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teixeira, L. R. Articles by Marchi, E. Search for Related Content PubMed Articles by Teixeira, L. R. Articles by Marchi, E.

INFLUENCE OF THE ANTIINFLAMMATORY COX-2 INHIBITOR (PARECOXIB) ON EXPERIMENTAL PLEURODESIS INDUCED BY TALC OR SILVER NITRATE

Pulmonary Division Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil

PURPOSE: We have previously demonstrated that the anti-inflammatory drugs (corticosteroids or diclofenac) diminish the efficacy of pleurodesis induced by talc (TL) but not by silver nitrate (SN). In clinical practice, anti-inflammatory cyclooxygenase-2 inhibitors (COX-2) are used to control pain and inflammation. The aim of this study was to evaluate the influence of systemic COX2 (Parecoxib) in pleurodesis induced by TL or SN.

METHODS: Forty rabbits received intrapleural injection of 0.5% SN or 400 mg/kg TL. The first group (20 animals) received intramuscular injections of Parecoxib (1mg/Kg/day) during the first seven days, then one injection a week until the end of the study; the second group did not receive COX-2. After 1, 2, 7 or 28 days, five animals in each group were killed and macro and microscopic analyses were performed using scores from 0 to 4. Statistical analysis: t-test.

RESULTS: The systemic injection of COX-2 reduced the gross adhesions at the 2nd and 7th day only in the talc group (*p<0.05); however after 28 days no statistical difference was observed. Microscopic pleural inflammation decreased after 28 days in both groups (*p<0.05). No changes were observed in pleural fibrosis(Figure).

CONCLUSION: The systemic injection of Parecoxib did not interfere in the effectiveness of pleurodesis induced by silver nitrate or talc.

CLINICAL IMPLICATIONS: If these results can be extrapolated to clinical practice, anti-inflammatory cyclooxygenase-2 inhibitors (COX-2) may be used in patients submitted to pleurodesis.

DISCLOSURE: Lisete Teixeira, No Financial Disclosure Information; No Product/Research Disclosure Information

This article has been cited by other articles:

				H. O. Coxson Chairman's Summary Proceedings of the ATS, December 15, 2008; 5(9): 874 - 877. [Full Text] [PDF]

				M. Nishimura Application of Three-Dimensional Airway Algorithms in a Clinical Study Proceedings of the ATS, December 15, 2008; 5(9): 910 - 914. [Abstract] [Full Text] [PDF]

				J. D. Newell Jr. Quantitative Computed Tomography of Lung Parenchyma in Chronic Obstructive Pulmonary Disease: An Overview Proceedings of the ATS, December 15, 2008; 5(9): 915 - 918. [Abstract] [Full Text] [PDF]

				H. O. Coxson, P. V. Nasute Fauerbach, C. Storness-Bliss, N. L. Muller, S. Cogswell, D. H. Dillard, C. L. Finger, and S. C. Springmeyer Computed tomography assessment of lung volume changes after bronchial valve treatment Eur. Respir. J., December 1, 2008; 32(6): 1443 - 1450. [Abstract] [Full Text] [PDF]

				P. J. Friedman Imaging Studies in Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 494 - 500. [Abstract] [Full Text] [PDF]